Building therapies for oncology and autoimmunity
RedRidge Bio is a clinical-stage biotech company specializing in the discovery and development of biparatopic antibodies (BPAs) — antibodies that simultaneously target two distinct epitopes on a single protein — for cancer and autoimmune diseases. The company's lead assets include biparatopic antibody-drug conjugates for liquid and solid tumors, as well as tissue-tethered immune cell modulators for inflammatory diseases. RedRidge Bio combines high-throughput screening, structural biology, and disease biology expertise to engineer best-in-class therapeutics with superior efficacy and long-term safety profiles.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountApr 2025
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Clinical-stage biopharma developing precision medicines for cancer and other serious diseases usi...
Biotech venture firm and therapeutics accelerator that invests at seed stage and acts as a drug d...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Uses AI to analyze natural chemistry and accelerate discovery of new medicines for biopharma and ...
